Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06119932
Other study ID # Subdural hematoma
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date November 1, 2023
Est. completion date October 1, 2024

Study information

Verified date October 2023
Source Assiut University
Contact Mohammed Lotfi, Resident
Phone 01147341661
Email Mohammedlotfi029@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To evaluate the outcome of one burrhole evacuation for subdural hematoma and it has the same result of traditional two burrhole


Description:

- Subdural hematoma (SDH): abnormal Collection of Liquefied blood degradation underneath the dura matter (1.2.3). - one of the most frequent types of intracranial haemorrhage, That is still associated with significant morbidity (1.4.5). - The SDH: is a common disease in elderly Patient, and Its Incidence is highest in persons older than 70 Years of age (1.5). - Types of Subdural hematoma(18.19) 1- Acute: present within 48-72 hours of injury. 2. Sub-acute: manifest itself between 3-20 day. 3- Chronic (CH): produce symptoms from 3 weeks to several months after injury Risk Factors: (7.8.9.10.11.12) 1. Trauma; mostly minor Trauma, Approximately two thirds of The Patients have suffered one. Reports exist of chronic SDH due to birth trauma in neonates. 2. Advanced age: The elderly are at risk due to: 1. brain atrophy, whereby The bridging veins are stretched and become more fragile. 2. Older People tend to fall more often and Suffer minor head trauma. 3. With increase age, The incidence of blood Thinner administration raises leading to increased risk for haemorrhage 3. Chronic alcoholism: 4. Gender: men, from all age groups, suffer higher rates of chsDH than woman. 5. CoagulaPathy: Therapeutic anticoagulation and antiplatelet therapy. 6. Medical Conditions: sepsis, hepatic failure, hemophilia, DIC and renal dialysis. 7. Intracranial hypotension: as after ventriculoperitoneal shunt. clinical presentation (1.13) - Symptoms of increase intra cranial pressure: Headache, Nausea, vomiting. - Focal neurological deficit - (weakness, aphasia). - Disturbed conscious level (DCL) - Seizures - Imaging investigation: CT brain (14.15) - Management : (1.6.16.17) 1. Conservative: A watch, wait and re-scan Policy is usually recommended in asymptomatic or minimally symptomatic patient with a thin CHSDH. 2. Surgical: For symptomatic (SDH) a- burr hole drainage B-twist drill drainage c- craniotomy - prognostic factors : (2.5) 1- age of patient 2- Associated chronic diseases like hypertension, liver diseases …….Etc 3- Laboratory investigation like Hb , platlate count ,pc,and PT. 5- Hematoma thickness 6- number of burr hole : one or two burr hole


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 35
Est. completion date October 1, 2024
Est. primary completion date July 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with subdural hematoma either unilateral or bilateral - fit for surgery - Chronic SDH - Subacute SDH - Age: patients older than 18 years old - SEX: Both sex Exclusion Criteria: - Patients unfit for surgery - Acute SDH - subdural hyroma - subdural empyema - patient treated conservatively

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Evacuation for subdural hematoma by one burrhole
Evacuation for subdural hematoma by one burrhole

Locations

Country Name City State
Egypt Mohammed lotfi abdelkareem Assiut
Egypt Mohammed lotfi abdelkareem Minya Malawi

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary ClinicalEvaluation of evacuation for subdural hematoma by one burrhole glasgo coma scale,
neurological deficit,
clinical symptoms (seizures) .
72 hours post operative
Secondary Radiological evaluation for outcome Nearly gross total evacuation according to confirmation by postoperative CT brain 72 hours post operative
See also
  Status Clinical Trial Phase
Recruiting NCT04402632 - Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma N/A
Completed NCT03496545 - Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury Phase 1/Phase 2
Terminated NCT05472766 - Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma N/A
Not yet recruiting NCT06052124 - Augmented Reality for Subdural Drain Placement N/A
Completed NCT02368366 - Comparative Effectiveness of Family Problem-Solving Therapy (F-PST) for Adolescent TBI N/A
Terminated NCT01463878 - Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit Study Phase 4
Completed NCT02618382 - A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population Phase 4
Recruiting NCT04923984 - Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can) N/A
Completed NCT03153150 - Start or STop Anticoagulants Randomised Trial (SoSTART) Phase 3
Completed NCT04270955 - Dartmouth Middle Meningeal Embolization Trial (DaMMET) N/A
Recruiting NCT06067750 - Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
Not yet recruiting NCT05713630 - The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma Phase 3
Withdrawn NCT01605357 - Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury Phase 1/Phase 2
Withdrawn NCT04500795 - Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma N/A
Recruiting NCT04170582 - Patient Registry for Patients With Chronic Subdural Hematoma
Recruiting NCT05649904 - AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis N/A
Recruiting NCT04211233 - Diagnostic Subdural EEG-electrode And Subdural hEmatoma (DISEASE) N/A